Autolus Therapeutics Enters Material Definitive Agreement
Ticker: AUTL · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1730463
| Field | Detail |
|---|---|
| Company | Autolus Therapeutics PLC (AUTL) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.000042 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, partnership
Related Tickers: AUTL
TL;DR
Autolus signed a big deal, details TBD.
AI Summary
Autolus Therapeutics plc announced on September 10, 2024, that it has entered into a material definitive agreement. The filing does not provide specific details regarding the nature of the agreement, the counterparty, or any associated financial figures.
Why It Matters
This filing indicates a significant new contract or partnership for Autolus Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement.
Key Players & Entities
- Autolus Therapeutics plc (company) — Registrant
FAQ
What is the nature of the material definitive agreement entered into by Autolus Therapeutics plc?
The filing does not specify the nature of the material definitive agreement.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the identity of the counterparty.
What is the effective date of this material definitive agreement?
The earliest event reported is September 10, 2024.
Are there any financial terms or obligations associated with this agreement disclosed in the filing?
No financial terms or obligations are disclosed in this filing.
Does this agreement represent a new partnership, acquisition, or other significant business development for Autolus Therapeutics?
The filing states it is an 'Entry into a Material Definitive Agreement' but does not provide further specifics on its type.
Filing Stats: 762 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2024-09-13 09:08:31
Key Financial Figures
- $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec
Filing Documents
- autl-20240910.htm (8-K) — 32KB
- 0001730463-24-000099.txt ( ) — 191KB
- autl-20240910.xsd (EX-101.SCH) — 2KB
- autl-20240910_def.xml (EX-101.DEF) — 15KB
- autl-20240910_lab.xml (EX-101.LAB) — 26KB
- autl-20240910_pre.xml (EX-101.PRE) — 16KB
- autl-20240910_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement On September 10, 2024, Autolus Limited and Autolus Therapeutics plc (collectively, the "Company") entered into agreements that amend the lease agreement between them and Forge Life Sciences Nominee 1 Ltd and Forge Life Sciences Nominee 2 Ltd (collectively, the "Landlord"), dated September 19, 2023, for the Company's Nucleus manufacturing facility in Stevenage, U.K.. The transaction documents include a Deed of Variation to the existing lease, a Licence for Alterations, and a Capital Contribution Deed (collectively, the "Lease Amendments"). Pursuant to the Lease Amendments, the Landlord will provide up to 18.5 million of funding for specified improvements to the Nucleus facility, including the creation and fit out of additional clean rooms for product manufacture, which the Company has agreed to complete on a mutually agreed schedule. Once the improvements are complete, the annual rent payable by the Company under the lease for the remainder of the term will increase by approximately 1.84 million or, if greater, a specified percentage of the funding provided by the Landlord for such improvements, subject to an overall maximum annual rent increase of 2.19 million. The Lease Amendments do not affect the lease term, which continues to run until September 2043. Due to a familial relationship between one of the Company's directors and a senior executive of the Landlord's parent company, the Lease Amendments were approved by the audit committee of the Company's board of directors in accordance with the Company's Related Person Transactions Policy. The foregoing summary of the material terms of the Lease Amendments does not purport to be complete and is qualified in its entirety by reference to such Lease Amendments, which will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: September 13, 2024 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer